SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs. The global GLP-1 market could total more ...

Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...

The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in ...

Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the ...

As GLP-1 receptor agonists reshape obesity treatment, a new medical perspective published in JAMA, underscores a persistent ...

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at ...

Izicopan is an investigational next-generation oral C5aR1 inhibitor designed to achieve differentiated pharmacological properties, with the potential for improved efficacy and safety. The marketed ...

The Opti-GAIN study from Complement Therapeutics is assessing the safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD) of CTx001. A first-in-human ...

Atherosclerosis is a lipid-driven chronic inflammatory disease that is modulated by innate and adaptive immunity including humoral immunity. Importantly, antibody alterations achieved by genetic means ...

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...

FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...